Non-apoptotic programmed cell deaths in diabetic pulmonary dysfunction: the new side of advanced glycation end products

Front Endocrinol (Lausanne). 2023 Oct 26:14:1126661. doi: 10.3389/fendo.2023.1126661. eCollection 2023.

Abstract

Diabetes mellitus (DM) is a chronic metabolic disorder that affects multiple organs and systems, including the pulmonary system. Pulmonary dysfunction in DM patients has been observed and studied for years, but the underlying mechanisms have not been fully understood. In addition to traditional mechanisms such as the production and accumulation of advanced glycation end products (AGEs), angiopathy, tissue glycation, oxidative stress, and systemic inflammation, recent studies have focused on programmed cell deaths (PCDs), especially the non-apoptotic ones, in diabetic pulmonary dysfunction. Non-apoptotic PCDs (NAPCDs) including autophagic cell death, necroptosis, pyroptosis, ferroptosis, and copper-induced cell death have been found to have certain correlations with diabetes and relevant complications. The AGE-AGE receptor (RAGE) axis not only plays an important role in the traditional pathogenesis of diabetes lung disease but also plays an important role in non-apoptotic cell death. In this review, we summarize novel studies about the roles of non-apoptotic PCDs in diabetic pulmonary dysfunction and focus on their interactions with the AGE-RAGE axis.

Keywords: advanced glycosylation end products; diabetic pulmonary dysfunction; inflammation; non-apoptotic programmed cell deaths; oxidative stress.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Autophagic Cell Death*
  • Diabetes Mellitus*
  • Glycation End Products, Advanced / metabolism
  • Humans
  • Receptor for Advanced Glycation End Products / metabolism

Substances

  • Glycation End Products, Advanced
  • Receptor for Advanced Glycation End Products

Grants and funding

This study was supported by CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-005 and 2019-I2M-2-008), the Beijing Municipal Science and Technology Commission (Z201100005520025), National High Level Hospital Clinical Research Funding (2022-PUMCH-A-107, 2022-PUMCH-C-020), the National Natural Science Foundation of China (81471615, 81601430), and Fundamental Research Funds for the Central Universities (3332021006).